Updated warning on kidney impairment for Reclast
Thursday 15 September 2011
The FDA has approved an update to the label for Reclast (zoledronic acid) to reflect the risk of renal failure. Kidney failure is a rare but serious potential outcome associated with the use of Reclast in patients who already have risk factors for renal problems. Zoledronic acid is used to treat bone problems that may occur with cancer. It is also sold under the name Zometa.
>> http://www.oncologystat.com/news/FDA_Drug_Safety_Communication_New_Contraindication_and_Updated_Warning_on_Kidney_Impairment_for_Reclast_Zoledronic_Acid.html
European Oncology Nursing SocietyAvenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu